Malignant hyperthermia or hyperpyrexia (Q41406): Difference between revisions
From determinar.ia.br - Determine suas informações
Changed an Item |
Changed an Item |
||
| Property / Linked ICD 10 | |||
| Property / Linked ICD 10: G71.8 / rank | |||
Normal rank | |||
Latest revision as of 07:34, 13 August 2026
Malignant hyperthermia is a pharmacogenetic disorder of skeletal muscle that presents as a hypermetabolic response to potent volatile anaesthetic gases such as halothane, sevoflurane, desflurane and the depolarizing muscle relaxant succinylcholine, and rarely in humans, to stresses such as vigorous exercise and heat. May be caused by a mutation in the Ryonadine Receptor 1 gene.
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | 8C78 |
||
| English | Malignant hyperthermia or hyperpyrexia |
Malignant hyperthermia is a pharmacogenetic disorder of skeletal muscle that presents as a hypermetabolic response to potent volatile anaesthetic gases such as halothane, sevoflurane, desflurane and the depolarizing muscle relaxant succinylcholine, and rarely in humans, to stresses such as vigorous exercise and heat. May be caused by a mutation in the Ryonadine Receptor 1 gene. |
Statements
CID11:8C78
0 references
dki-india-8C78
0 references
Concluído
0 references
13 August 2026
0 references
